PHLPP2 Antibody
| Code | Size | Price |
|---|
| PSI-7021-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7021-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
PHLPP2 Antibody: PHLPPL, KIAA0931, PHLPPL, PH domain leucine-rich repeat-containing protein phosphatase 2, PH domain leucine-rich repeat-containing protein phosphatase-like, PHLPP-like
Application Note:
PHLPP2 antibody can be used for detection of PHLPP2 by Western blot at 1 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
PHLPP2 Antibody: PHLPP2 is a member of the serine/threonine phosphatase family, which are important regulators of Akt serine-threonine kinases (AKT1, AKT2, AKT3) and conventional/novel protein kinase C (PKC) isoforms. PHLPP1 and PHLPP2 have a similar domain structure and have been shown to dephosphorylate and inactivate, distinct Akt isoforms, at one of the two critical phosphorylation sites required for activation: Serine473. PHLPP2 dephosphorylates AKT1 and AKT3, whereas PHLPP1 is specific for AKT2 and AKT3. PHLPP1 promotes apoptosis and may act as a tumor suppressor. PHLPP2 associates with and is inhibited by adenylyl cyclase type 6 (AC6), thereby allowing Akt activation.
Background References:
- Brognard J and Newton AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol. Metab. 2008; 19:223-30.
- Gao T, Furnari F and Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 2005; 18:13-24.
- Brognard J, Sierecki E, Gao T, et al. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 2007; 25:917-31
- Gao MH, Miyanohara A, Feramisco JR, et al. Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6. Biochem. Biophys. Res. Commun. 2009; 384:193-8.
Buffer:
PHLPP2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
PHLPP2 antibody was raised against a 20 amino acid synthetic peptide near the carboxy terminus of human PHLPP2.
The immunogen is located within the last 50 amino acids of PHLPP2.
The immunogen is located within the last 50 amino acids of PHLPP2.
NCBI Gene ID #:
23035
NCBI Official Name:
PH domain and leucine rich repeat protein phosphatase 2
NCBI Official Symbol:
PHLPP2
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
156 kDa
Protein Accession #:
NP_055835
Protein GI Number:
65301141
Purification:
PHLPP2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
At least three isoforms are known to exist; this antibody will detect the two largest isoforms. PHLPP2 antibody is predicted to not cross react with PHLPP1.
Swissprot #:
Q6ZVD8
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | PHLPP2 Peptide | PSI-7021P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|